Norbert Bräu

Data from Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma

Jessie Torgersen, Tamar H. Taddei, Lesley S. Park, Dena M. Carbonari et autres

AbstractBackground: The incidence of hepatocellular carcinoma (HCC) is substantially higher among HIV-infected (HIV+) than uninfected persons. It remains unclear if HCC in the setting of HIV infection is morphologically distinct or more aggressive. Methods: We evaluated differences in tumor pathology in a …

Supplementary Tables 1-9 from Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma

Jessie Torgersen, Tamar H. Taddei, Lesley S. Park, Dena M. Carbonari et autres

Supplemental Table 1. Current Procedural Terminology (CPT) codes identifying treatments for hepatocellular carcinoma. Supplemental Table 2. Clinical characteristics of patients with confirmed hepatocellular carcinoma diagnosis in the Veterans Aging Cohort Study (2000-2015), by diagnostic modality. Supplemental Table 3. Factors associated with all-cause …

Impact of High‐Titer Convalescent Plasma on Clinical and Virologic Outcomes Among Veterans Hospitalized With SARS‐CoV‐2 Infection: VA CoronavirUs Research and Efficacy Studies‐1 (VA CURES‐1)

Edward N. Janoff, Mei‐Chiung Shih, Curtis J. Donskey, Ilana Belitskaya‐Lévy et autres

In the initial absence of proven therapies, empirical COVID-19 convalescent plasma (CCP) was rapidly introduced for individuals hospitalized for COVID-19. Seventy-five participants were randomized from November 2020 to June 2021 in a double-blind, multi-site, placebo-controlled, randomized trial (VA CURES-1) evaluating the impact …

us (code pays fourni par la source)

Hepatocellular carcinoma in people living with HIV

Claudia Angela Maria Fulgenzi, Alessia Dalla Pria, Alberto Giovanni Leone, Ciro Celsa et autres

People living with HIV (PLWH) carry a higher risk of developing chronic liver disease and hepatocellular carcinoma (HCC). This relates to shared transmission pathways of HIV and viral hepatitis and a plethora of direct and indirect effects of HIV on the progression …

gb, it, es, at, us (code pays fourni par la source)

Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status

Vincent Lo Re, Craig Newcomb, Dena M. Carbonari, Alyssa Mezochow et autres

BACKGROUND: Studies evaluating the hepatic safety of medications have been limited by the inability to control for confounding from receipt of other hepatotoxic drugs. OBJECTIVE: The objective of this study was to develop an index (Hepatotoxicity Score) to adjust for concomitant hepatotoxic …

us, gb (code pays fourni par la source)

Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data

Jessie Torgersen, Alyssa Mezochow, Craig Newcomb, Dena M. Carbonari et autres

Importance: Current approaches to classify the hepatotoxic potential of medications are based on cumulative case reports of acute liver injury (ALI), which do not consider the size of the exposed population. There is little evidence from real-world data (data relating to patient …

us, gb (code pays fourni par la source)

Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma

David J. Pinato, Takahiro Kaneko, Antonio D’Alessio, Alejandro Forner et autres

Background & Aims HIV-seropositivity shortens survival in patients with hepatocellular carcinoma (HCC). Although risk factors for HCC including HCV infection can influence T cell phenotype, it is unknown whether HIV can influence functional characteristics of the T cell infiltrate. Methods From the …

it, gb, jp, es, us (code pays fourni par la source)

Influence of Cancer on COVID-19 Incidence, Outcomes, and Vaccine Effectiveness: A Prospective Cohort Study of U.S. Veterans

Harshraj Leuva, Mengxi Zhou, Norbert Bräu, Sheldon T. Brown et autres

us (code pays fourni par la source)

Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)

Iván O. Rosas, Norbert Bräu, Michael R. Waters, Ronaldo C. Go et autres

Background: In COVACTA, a randomised, placebo-controlled trial in patients hospitalised with coronavirus disease-19 (COVID-19), tocilizumab did not improve 28-day mortality, but shortened hospital and intensive care unit stay. Longer-term effects of tocilizumab in patients with COVID-19 are unknown. Therefore, the efficacy and …

us, gb, ca, es, fr, dk, it, nl, ch (code pays fourni par la source)

Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation

Jessie Torgersen, Craig Newcomb, Dena M. Carbonari, Christopher T. Rentsch et autres

us, gb (code pays fourni par la source)

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

Iván O. Rosas, Norbert Bräu, Michael R. Waters, Ronaldo C. Go et autres

BACKGROUND: Coronavirus disease 2019 (Covid-19) is associated with immune dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of tocilizumab, a monoclonal antibody against the interleukin-6 receptor, has resulted in better outcomes in patients with severe Covid-19 pneumonia in case reports and …

us (code pays fourni par la source)

COVID-19 in spinal cord injury patients at a veterans administration hospital: A case series

Marinella Galea, Michael A. Gelman, Vincent P. Galea, Krutika Parasar Raulkar et autres

OBJECTIVE: To describe the clinical features and disease course of COVID-19 in veterans with spinal cord injury (SCI). DESIGN: Case series of consecutive veterans with SCI treated at a single center. SETTING: SCI Unit at an urban Veterans Administration hospital at the …

us (code pays fourni par la source)